We are live on
!
Find out more
ACM
ADAR1 Capital Management Portfolio holdings
AUM
$1.7B
1-Year Est. Return
340.85%
This Fund
S&P 500
This Quarter
Est. Return
+8.25%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.7B
AUM Growth
+$337M
(+25%)
Cap. Flow
+$320M
Cap. Flow
% of AUM
18.81%
Top 10 Holdings %
Top 10 Hldgs %
39.64%
Holding
351
New
78
Increased
102
Reduced
60
Closed
41
Top Buys
| 1 |
Beam Therapeutics
BEAM
|
+$40.1M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
+$37.1M |
| 3 |
Denali Therapeutics
DNLI
|
+$36.2M |
| 4 |
Inspire Medical Systems
INSP
|
+$27.3M |
| 5 |
Vir Biotechnology
VIR
|
+$21.9M |
Top Sells
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$39.4M |
| 2 |
RAPT
RAPT Therapeutics
RAPT
|
+$17.3M |
| 3 |
CDTX
Cidara Therapeutics
CDTX
|
+$13.2M |
| 4 |
Fulcrum Therapeutics
FULC
|
+$10.4M |
| 5 |
Arbutus Biopharma
ABUS
|
+$9.98M |
Sector Composition
| 1 | Healthcare | 88.42% |
| 2 | Financials | 1.51% |
| 3 | Technology | 0.08% |
| 4 | Industrials | 0.08% |
| 5 | Materials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Elanco Animal Health
ELAN
$12.9B
| $479K | 0.03% |
20,000
| – | – |
|
|
NVO
202
CALL
Novo Nordisk
NVO
$228B
| $478K | 0.03% |
+13,000
| New | +$616K |
|
203
Phathom Pharmaceuticals
PHAT
$881M
| $477K | 0.03% |
42,900
| – | – |
|
204
Madrigal Pharmaceuticals
MDGL
$12.4B
| $469K | 0.03% |
895
| – | – |
|
205
PolyPid
PYPD
$99.1M
| $455K | 0.03% |
103,950
| – | – |
|
206
Alibaba
BABA
$284B
| $449K | 0.03% |
3,578
| – | – |
|
207
Core Scientific
CORZ
$6.65B
| $449K | 0.03% |
30,000
| – | – |
|
|
WHWK
208
Whitehawk Therapeutics
WHWK
$189M
| $443K | 0.03% |
128,503
+50,910
| +66% | +$159K |
|
209
Natera
NTRA
$39.5B
| $429K | 0.03% |
2,147
| – | – |
|
210
VistaGen Therapeutics
VTGN
$9.71M
| $429K | 0.03% |
751,141
+127,566
| +20% | +$77.5K |
|
211
TherapeuticsMD
TXMD
$23.5M
| $423K | 0.02% |
209,210
| – | – |
|
212
CALL
Ultragenyx Pharmaceutical
RARE
$2.97B
| $419K | 0.02% |
20,000
+10,000
| +100% | +$225K |
|
213
Syndax Pharmaceuticals
SNDX
$2.03B
| $409K | 0.02% |
17,500
+5,500
| +46% | +$120K |
|
|
TECX
214
Tectonic Therapeutic
TECX
$587M
| $402K | 0.02% |
13,001
-17,006
| -57% | -$419K |
|
215
Entrada Therapeutics
TRDA
$268M
| $385K | 0.02% |
+30,500
| New | +$350K |
|
216
Biohaven
BHVN
$2.15B
| $379K | 0.02% |
44,777
+10,500
| +31% | +$115K |
|
217
Merck
MRK
$316B
| $378K | 0.02% |
3,140
-6,500
| -67% | -$750K |
|
218
Verastem
VSTM
$495M
| $377K | 0.02% |
+71,100
| New | +$438K |
|
219
CALL
MoonLake Immunotherapeutics
MLTX
$1.61B
| $373K | 0.02% |
+20,000
| New | +$331K |
|
220
Regenxbio
RGNX
$583M
| $372K | 0.02% |
44,416
-100,432
| -69% | -$1.06M |
|
221
Adicet Bio
ACET
$77.5M
| $367K | 0.02% |
53,827
-74,819
| -58% | -$560K |
|
222
Legend Biotech
LEGN
$4.38B
| $362K | 0.02% |
+20,000
| New | +$381K |
|
223
Surrozen
SRZN
$256M
| $350K | 0.02% |
+12,000
| New | +$288K |
|
224
Zentalis Pharmaceuticals
ZNTL
$324M
| $338K | 0.02% |
144,636
+64,636
| +81% | +$167K |
|
|
BCYC
225
Bicycle Therapeutics
BCYC
$286M
| $331K | 0.02% |
+71,298
| New | +$407K |
|
Similar funds
RSCM
AAM
SGI
WAS
BCM
SWM
TCM
ISS